Related Experiment Video
Updated: Apr 28, 2026

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome
Published on: March 23, 2022
Dysregulation of cardiolipin biosynthesis in pediatric heart failure
Kathryn C Chatfield1, Genevieve C Sparagna2, Carmen C Sucharov3
1Department of Pediatrics, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, CO, USA.
Insights
Pediatric idiopathic dilated cardiomyopathy (IDC) shows lower levels of cardiolipin (CL), a vital mitochondrial phospholipid. These findings suggest unique age-related mechanisms contribute to heart dysfunction in children with IDC.
Area of Science:
- Cardiology
- Mitochondrial Biology
- Biochemistry
Background:
- Cardiolipin (CL) is essential for mitochondrial function and its abnormalities are linked to heart failure.
- Previous studies identified CL alterations in adult and rodent failing hearts.
Purpose of the Study:
- To investigate cardiolipin content and its related pathway enzyme expression in pediatric idiopathic dilated cardiomyopathy (IDC).
- To compare these findings with adult heart failure and identify age-specific disease mechanisms.
Main Methods:
- Cross-sectional analysis of 119 pediatric IDC and non-failing (NF) control myocardial tissue samples.
- Quantification of total CL and CL species using electrospray ionizing mass spectrometry.
- Measurement of CL pathway enzyme gene expression via RT-PCR.
Main Results:
- Pediatric IDC hearts exhibited significantly lower total CL and beneficial (18:2)4CL species compared to NF controls.
- Mitochondrial content remained unchanged, indicating specific CL pathway defects.
- Altered expression of CL biosynthesis, remodeling, and degradation enzymes was observed, differing from adult heart failure patterns.
Conclusions:
- Lower cardiolipin levels and altered enzyme expression are characteristic of pediatric IDC.
- These molecular changes are distinct from adult heart failure, suggesting unique pediatric-specific mechanisms.
- Findings highlight the critical role of cardiolipin metabolism in pediatric heart disease.
Abstract:
Cardiolipin, a unique phospholipid in the inner mitochondrial membrane, is critical for optimal mitochondrial function. CL abnormalities have been demonstrated in the failing rodent and adult human heart. The aim of this study was to determine whether abnormalities in CL content and the CL biosynthesis and remodeling pathways are present in pediatric idiopathic dilated cardiomyopathy (IDC). A cross-sectional analysis of myocardial tissue from 119 IDC and non-failing (NF) control samples was performed. Electrospray ionizing mass spectrometry was used to measure total CL and CL species content in LV tissue. RT-PCR was employed to measure gene expression of the enzymes in the CL biosynthesis and remodeling pathways in both the adult and pediatric heart. Significantly lower total and (18:2)4CL (the beneficial species) content was demonstrated in myocardium from pediatric patients with IDC compared to NF controls. Analysis of mitochondrial gene transcripts was used to demonstrate that there is no decrease in mitochondrial content. Expression of two biosynthesis enzymes and one remodeling enzyme was significantly lower in pediatric IDC compared to NF controls. Expression of two phospholipases involved in CL degradation were also altered, one up- and one down-regulated. Except for one remodeling enzyme, these changes are unique from those in the failing adult heart. Similar to what has been seen in adults and in a rat model of IDC, total and (18:2)4CL are lower in pediatric IDC. Unique CL species profiles are seen in heart tissue from children with IDC compared to adults. Differences in CL biosynthesis and remodeling enzyme expression likely explain the differences in CL profiles observed in IDC and implicate unique age-related mechanisms of disease.
Related Concept Videos
Pathophysiology of Heart Failure
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy

